Study S000329
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)
Registration
Registered primary outcomes
- Change From Baseline in HbA1c (Glycosylated Haemoglobin) [Week 0, week 56]
Linked records (18)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0019127 | Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Mosenzon O, Cardiovascular diabetology | 2022 | Randomized trial | PMID 36056351DOI | cites ClinicalTrials.gov:NCT01885208; registry reference DERIVED:36056351 |
| R0012216 | Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10. Capehorn M, Diabetes therapy : research, treatment and education of diabetes and related disorders | 2020 | Randomized trial | PMID 32193837DOI | cites ClinicalTrials.gov:NCT01885208; registry reference DERIVED:32193837 |
| R0015927 | Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. DeSouza C, The Journal of clinical endocrinology and metabolism | 2020 | Randomized trial | PMID 31769496DOI | cites ClinicalTrials.gov:NCT01885208; registry reference DERIVED:31769496 |
| R0018492 | Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. Lingvay I, The Journal of clinical endocrinology and metabolism | 2020 | Systematic review | PMID 32827435DOI | cites ClinicalTrials.gov:NCT01885208; registry reference DERIVED:32827435 |
| R0018529 | Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Husain M, Cardiovascular diabetology | 2020 | Randomized trial | PMID 32998732DOI | cites ClinicalTrials.gov:NCT01885208; registry reference DERIVED:32998732 |
| R0018857 | Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Husain M, Diabetes, obesity & metabolism | 2020 | Other | PMID 31903692DOI | cites ClinicalTrials.gov:NCT01885208; registry reference DERIVED:31903692 |
| R0009176 | Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach. Overgaard RV, Diabetes, obesity & metabolism | 2019 | Other trial | PMID 30047216DOI | registry reference RESULT:30047216 |
| R0009827 | GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES. Rodbard HW, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists | 2019 | Other trial | PMID 30865526DOI | registry reference BACKGROUND:30865526 |
| R0012485 | Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials. Jendle J, Diabetes, obesity & metabolism | 2019 | Other trial | PMID 31215727DOI | cites ClinicalTrials.gov:NCT01885208; cites EudraCT:2012-004826-92; registry reference DERIVED:31215727 |
| R0013158 | Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Aroda VR, Diabetes & metabolism | 2019 | Other trial | PMID 30615985DOI | registry reference RESULT:30615985 |
| R0017182 | Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Malkin SJP, Diabetes therapy : research, treatment and education of diabetes and related disorders | 2019 | Nonrandomized study | PMID 30535837DOI | registry reference RESULT:30535837 |
| R0017746 | Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. Fonseca VA, The Journal of clinical endocrinology and metabolism | 2019 | Other | PMID 30938762DOI | registry reference BACKGROUND:30938762 |
| R0013229 | Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. Carlsson Petri KC, Diabetes therapy : research, treatment and education of diabetes and related disorders | 2018 | Other trial | PMID 29907893DOI | cites ClinicalTrials.gov:NCT01885208; registry reference RESULT:29907893 |
| R0018825 | Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Ahrén B, Diabetes, obesity & metabolism | 2018 | Randomized trial | PMID 29766634DOI | registry reference RESULT:29766634 |
| R0020680 | Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Ahmann AJ, Diabetes care | 2018 | Randomized trial | PMID 29246950DOI | cites ClinicalTrials.gov:NCT01885208; registry reference RESULT:29246950 |
| R0020727 | Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Petri KCC, Diabetes, obesity & metabolism | 2018 | Randomized trial | PMID 29748996DOI | registry reference RESULT:29748996 |
| R0022511 | Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials. Warren M, Diabetes, obesity & metabolism | 2018 | Randomized trial | PMID 29687620DOI | registry reference RESULT:29687620 |
| R0023345 | Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. DeVries JH, Diabetes, obesity & metabolism | 2018 | Randomized trial | PMID 29862621DOI | registry reference RESULT:29862621 |